Article
Risk factors for inhibitor development in hemophilia A.
Haematologica - 1 Oct 2000
Oldenburg J, Brackmann H H, Schwaab R
Abstract excerpt
The development of anti-factor-VIII-antibodies represents the most serious complication of factor VIII concentrate therapy, affecting about 30% of patients with severe hemophilia A. The genetics of the patients, comprising the factor VIII gene mutation and the immune response genes (MHC), have been shown to influence the risk of inhibitor formation. Severe molecular defects within the factor VIII gene, such as...
Topics
- Genetic Predisposition to Disease
- Hemophilia A
- Humans
- Isoantibodies
- Mutation
- Risk Factors